Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 65
SponsorMasonic Cancer Center, University of Minnesota

About this trial

This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.

Eligibility criteria

Qualifiers

Diagnosis of Fanconi anemia

Age <65 years of age

Severe aplastic anemia (SAA)

Myelodysplastic features

Disqualifiers

Pregnant or breastfeeding as the treatment used in this study are Pregnancy Category D. Females of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days of study registration

Active, uncontrolled infection within 1 week prior to starting study therapy

Malignant solid tumor cancer within previous 2 years

an HLA-A, B, DRB1 matched sibling donor (matched sibling)

Trial design

Treatments tested in this trial

  • Total Body Irradiation (TBI) (Plan 1)
  • Cyclophosphamide (CY) (Plan 1)
  • Fludarabine (FLU)
  • Methylprednisolone (MP)
  • Donor mobilized PBSC infusion
  • G-CSF
  • Cyclophosphamide (CY) (Plan 2)
  • Rituximab
  • Busulfan
  • Alemtuzumab
  • Melphalan
  • Rituximab

Treatment groups

48 Participants
are divided into 5 treatment groups